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Abstract
Background: We assessed ovarian cancer screening outcomes in women with a positive family history of ovarian
cancer divided into a low-, moderate- or high-risk group for development of ovarian cancer.
Methods: 545 women with a positive family history of ovarian cancer referred to the Ovarian Screening Service at
the Royal Marsden Hospital, London from January 2000- December 2008 were included. They were stratified into
three risk-groups according to family history (high-, moderate- and low-risk) of developing ovarian cancer and
offered annual serum CA 125 and transvaginal ultrasound screening. The high-risk group was offered genetic
testing.
Results: The median age at entry was 44 years. The number of women in the high, moderate and low-risk groups
was 397, 112, and 36, respectively. During 2266 women years of follow-up two ovarian cancer cases were found:
one advanced stage at her fourth annual screening, and one early stage at prophylactic bilateral salpingo-
oophorectomy (BSO). Prophylactic BSO was performed in 138 women (25.3%). Forty-three women had an
abnormal CA125, resulting in 59 repeat tests. The re-call rate in the high, moderate and low-risk group was 14%,
3% and 6%. Equivocal transvaginal ultrasound results required 108 recalls in 71 women. The re-call rate in the high,
moderate, and low-risk group was 25%, 6% and 17%.
Conclusion: No early stage ovarian cancer was picked up at annual screening and a significant number of re-calls
for repeat screening tests was identified.
Keywords: ovarian cancer, screening, transvaginal ultrasound, serum CA125, BRCA gene mutation, bilateral sal-
pingo-oophorectomy
Background
Primary ovarian cancer is the fourth most common
cause of cancer-related death in the United Kingdom
with 4500 deaths each year [1]. The identification of
BRCA1 and BRCA2 gene mutations and their relation-
ship to ovarian cancer has resulted in an awareness of
family history in many women with ovarian cancer
[2-5]. Several studies have investigated the role of
screening in women with a positive family history of
ovarian cancer. Unfortunately, no clear evidence of the
efficacy of different screening strategies has been docu-
mented [6-8]. The normal life-time risk of developing
epithelial ovarian cancer in the UK is estimated to be 1-
1.5%. This risk is higher in women with a family history
of ovarian cancer and increases with the number of
affected relatives and the closeness of the relationship
[9]. In women with a known BRCA1 or BRCA2 gene
mutation the cumulative life-time risk of developing
ovarian cancer can be as high as 60% and 27%, respec-
tively, although it may be between 11-39% if the family
history is less strong [4,10,11]. The prognosis of ovarian
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cancer is good when diagnosed at an early stage (FIGO
stage I-II) with 80–95% 5-year survival. However, the
majority of ovarian cancer cases (70%) are detected at
an advanced stage with poor survival [12].
For women at high-risk of developing ovarian cancer,
management options still include a) ovarian cancer
screening by CA125 measurement and or transvaginal
ultrasound, with the intention to reduce mortality by
detecting ovarian cancer at an early stage, or b) prophy-
lactic bilateral salpingo-oophorectomy (BSO). The opti-
mal management policy in women with moderate or
low-risk of developing ovarian cancer remains unclear.
In this study, we assessed ovarian cancer screening
outcomes in women with a positive family history of
ovarian cancer stratified in a low, moderate or high-risk
group of developing ovarian cancer. We defined the
number of ovarian cancer cases identified, the number
of re-calls because of abnormal test results, and present
the characteristics of women who underwent prophylac-
tic BSO.
Methods
We conducted a retrospective audit of 545 women con-
secutively referred because of a positive family history of
ovarian cancer from January 2000 to December 2008 to
the Cancer Genetics Clinic at The Royal Marsden NHS
Foundation Trust in London, UK, for consideration of
annual screening. At the initial clinic visit the family his-
tory was documented, assessed and confirmed in a stan-
dardised format. Three risk categories were identified.
Women fulfilling the family history criteria shown in
Table 1 (NICE Guidelines on Familial Breast Cancer
2004), with an expected life-time risk of ovarian cancer
of greater than 10% were considered to be in the high-
risk group [13]. Women not meeting these criteria were
stratified either into the moderate-risk group (when life-
time risk = 4-10%), or in the low-risk group when there
was no significant family history of ovarian cancer.
Screening consisted of annual serum CA125 level mea-
surements and a transvaginal ultrasound. All scanning
was performed by one consultant radiologist (EM) with
many years of transvaginal ultrasound experience.
Screening results were interpreted and acted on by clini-
cians involved with no defined protocol other than using
the risk of malignancy index (RMI) only. Serum CA125
levels above 35 kU/L were considered abnormal. Abnor-
mal findings in at least one of the screening tests
prompted repeat testing within 3 months. Adjuvant ima-
ging (i.e. MRI) was organised urgently when malignancy
was suspected and, if indicated, a diagnostic surgical
procedure was performed (laparoscopy or laparotomy).
Women in the high-risk group were offered genetic test-
ing if possible (only if the affected relative could be
tested or if there were no living affected relatives a foun-
der mutation test could be found if she was from a rele-
vant ethnic group). Women in the moderate-risk group
were offered genetic testing only if indicated (e.g. if they
were from a founder group where testing indicated even
at moderate risk for ovarian cancer). Prophylactic BSO
was offered to all high-risk women when they completed
their family or reached the age of 40 years. During this
procedure an endometrial sampling was taken, as this is
standard practice in our centre.
The provision of ovarian screening was discontinued
at The Royal Marsden NHS Foundation Trust in 2004
as screening was concentrated in other centres, if appro-
priate; pending the results of studies of screening in
high-risk families (the UKFOCSS study). All patients
had a full family history taken out to third degree rela-
tives and their risk was reviewed by a cancer geneticist
(RE). Those patients who had been assessed as being at
high-risk for ovarian cancer were offered participation
in the UKFOCSS study (UK Familial Ovarian Cancer
Screening Study). Those who were been assessed as
being at moderate-risk were referred to St Georges Hos-
pital, London, one of the very few NHS Gynaecology
Departments which still offered ovarian cancer screening
outside a research study to moderate-risk women, or to
a local hospital if this was more convenient for the
woman. All other patients were considered low-risk,
indicating that some women formerly considered at
increased risk were reclassified as low-risk and advised
Table 1 Increased risk criteria in women with a family history of breast and ovarian cancer [13]
Criteria
1 Family contains 2 or more individuals with ovarian cancer who are first degree relatives
2 Family contains 1 individual with ovarian cancer and 1 individual with breast cancer diagnosed < 50 years who are first degree relatives
3 Family contains 1 individual with ovarian cancer and 2 individuals with breast cancer diagnosed < 60 years who are connected by first
degree relationships
4 Family contains an affected individual with a mutation in one of the known ovarian cancer predisposition genes BRCA1, BRCA2, MSH2,
MSH6, MLH1, PMS1 or PMS2
5 Family contains 3 individuals with colorectal cancer with at least 1 case diagnosed before 50 years and 1 case of ovarian cancer. All
individuals are connected by first degree relationships
6 Criteria 1,2 and 3 can be modified where paternal transmission is occurring, i.e. families where affected relatives are related by second
degree through an unaffected intervening male relative and a sister is affected are eligible
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that there was no indication for further screening and
were discharged. From 2004, new patients were still
initially assessed in our clinic but referred according to
risk group. Inclusion in the study ended in December
2008. The total number of prophylactic BSO was
recorded as were the number of repeat CA125 measure-
ments and transvaginal ultrasound visits due to abnor-
mal findings. The expected number of ovarian cancers
to be detected in this study was calculated, divided into
women years tested by risk category and age group
(using incidence rates of Antoniou et al, 2003) [4] Sta-
tistical analysis was performed using SPSS software (ver-
sion 17.0, SPSS Inc. Chicago).
As this was a clinical audit, a formal ethical review
was not required. According to hospital protocol the
study was reviewed and approved by the Royal Marsden
Clinical Audit Committee.
Results
A total of 545 women were included in this study and
all had at least one CA125 measurement and/or transva-
ginal ultrasound at baseline. The median age at entry
was 44 years old (range 25-74 years), with the majority
of women in the age group of 35 to 49 years old (61.3%)
(Table 2). Most women had at least one child (370 out
of 545; 67.9%). The total range was 0-7 children with a
median of 2 children.
At baseline, the majority of women was in the high-
risk group n = 397 (73%). The moderate- and low-risk
group consisted of 112 (21%) and 36 (6.6%) women,
respectively. In the high-risk group 140 women (35.3%)
underwent genetic testing and in 106 (76%) a genetic
mutation was identified. Among these women, 58 (55%)
women were BRCA1 gene mutation carriers and 45
(43%) women had a BRCA2 gene mutation. In 2 (1.9%)
an MLH1 gene defect mutation was identified. One
(0.9%) woman was diagnosed with both a BRCA1 and
BRCA 2 gene mutation. This 69 year old lady underwent
a hysteroscopy, dilatation and curettage for an endome-
trial polyp which revealed a grade 3 endometrioid ade-
nocarcinoma of the endometrium. She underwent a
laparoscopic hysterectomy and bilateral salpingo-
oophorectomy showing FIGO stage 1B endometrial can-
cer. Her ovaries and fallopian tubes were histologically
normal.
In 2 women, epithelial ovarian cancer was diagnosed.
The first case, a 50-year-old BRCA1 gene mutation car-
rier, presented at her fourth annual screening visit with
an elevated CA125 of 3874 kU/L and bilateral complex
ovarian masses with ascites on transvaginal ultrasound.
She was asymptomatic. Her previous screening CA125
levels and transvaginal ultrasounds did not show any
abnormalities. At her third annual screening visit, 14
months before she was diagnosed with ovarian cancer,
her CA125 was 8 kU/L She underwent optimal debulk-
ing surgery and the final histopathology revealed Stage
3C poorly differentiated serous papillary adenocarci-
noma of the ovary. The second ovarian cancer case was
found in a 40 year old BRCA1 gene mutation carrier.
She underwent a routine prophylactic BSO. The adnexa
were grossly normal but the histology revealed Stage 1A
poorly differentiated serous adenocarcinoma of the
ovary. Her preoperative CA125 was 30 kU/L and no
abnormalities were seen on transvaginal ultrasound. She
had been undergoing annual screening for 5 years. Both
patients are still alive after 6 and 4 years of follow-up,
respectively.
Prophylactic BSO was performed in 138 women (25%).
In most cases peritoneal washings and an endometrial sam-
ple were taken at the same time. Table 3 shows the charac-
teristics of women who underwent a prophylactic BSO.
The majority of women came from the high-risk group
(94%); 69 (53%) of whom had tested positive for a gene
mutation. None of the 8 moderate-risk women had had
genetic testing and in one of these women ovarian stromal
hyperplasia was found on histopathology. In the high-risk
group 3 women (2.4%) had an ovarian/tubal abnormality
showing cancer (Stage 1A, see above), tubal atypia and
struma ovarii, respectively. In 2 women an endometrial
abnormality was found; atypical hyperplasia and hyperpla-
sia, on hysterectomy and curettage, respectively.
A total of 2266 women years of follow-up were identi-
fied. The majority of women years (1623 women years)
were in the high-risk group, with 522 and 121 women
years in the moderate- and low-risk group, respectively.
A total of 3.89 (95% C.I. 0.22-7.22) ovarian cancer cases
were expected in the study population with 3.11, 0.68
and 0.11 cases in the high-, moderate-, and low-risk
groups, respectively.
Table 2 Patient characteristics at baseline with results of
genetic testing in the high-risk group
Patient
characteristics
N % Genetic
testing
N %
Age group < 35 years 42 7.7
35-49 years 334 61.3
≥ 50 years 169 31.0
Parity 0 133 24.4
≥ 1 370 67.9
Unknown 42 7.7
Risk group High-risk 397 72.8 Mutation
present
106 26.7
Negative 34 8.6
Not tested 257 64.7
Moderate-
risk
112 20.6 NA*
Low-risk 36 6.6 NA*
*NA = not applicable
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Table 4 shows the number of abnormal test results in
our cohort. In the high-risk group 37 out of 397 (9%) of
women had at least one elevated CA125 measurement
and 65 (16%) had at least one abnormal transvaginal
ultrasound scan during follow-up. In the moderate-risk
group these figures were 4% in both groups, and in the
low-risk group 3% and 6%, respectively. Equivocal trans-
vaginal ultrasound results prompted a total of 108 re-
calls in 71 women, with a majority of re-calls in the
high-risk group. The median age of women needing a
re-call transvaginal ultrasound was 43 years (range 29-
68). In only 7 high-risk women these abnormal transva-
ginal ultrasounds resulted in a prophylactic BSO. In all
these cases the final histopathology was normal. In all
other cases repeat transvaginal ultrasounds returned to
normal.
Forty-three women had an abnormal CA125 measure-
ment, resulting in a total of 59 repeat tests. The majority
of elevated CA125 was seen in the high-risk group. Only
one moderate-risk woman underwent a prophylactic
BSO because of 2 consecutive elevated CA125 measure-
ments (CA125 was 64 and 57 kU/l, respectively). Her
transvaginal ultrasounds were normal. No abnormalities
were found on final histopathology. In all, but three
women, CA125 results came back to normal. Among
these three women, one was diagnosed with advanced
ovarian cancer, one woman was pregnant and the third
diagnosed with recurrent breast cancer.
Discussion
In this retrospective study we assessed ovarian cancer
screening outcomes in 545 women with a positive his-
tory of ovarian cancer stratified into a low, moderate, or
high-risk group of developing ovarian cancer.
A total of 2 (0.4%) ovarian cancer cases were identi-
fied. None of them were found during screening. Most
studies looking at the effectiveness of ovarian cancer
screening found a higher incidence of ovarian cases of
about 1-3% [7,14]. Although our number of identified
ovarian cancer cases was low in comparison with these
studies, the annual screening detected the number of
cases expected for a population of this age, risk spec-
trum and duration of follow-up. One reason for the low
incidence of ovarian cancer is that our cohort included
moderate- and low-risk women. Laframboise et al.
reported 1 ovarian cancer in a series of 311 women of
which only 10% were BRCA gene mutation carriers [15].
In our high-risk group 35% underwent genetic testing
and in 76% a genetic mutation was identified. The rea-
son for this high percentage could be the high propor-
tion of Ashkenazi women (30%) and women with a
previous history of breast cancer (47%) in this group.
Table 3 Characteristics of 138 women who underwent prophylactic bilateral salpingo-oophorectomy
Risk Group N % Genetic testing N % Histopathology N %
Moderate 8 6.5 Not tested 8 100 NED 7 87.5
Ovarian stromal hyperplasia 1 12.5
High 130 94.2 Not tested 60 46.2
Negative 1 0.8
BRCA1 mutation 37 28.5
BRCA2 mutation 30 23.0
MLH1 mutation 2 1.5
NED 125 96.0
Cancer 1 0.8
Atypia tube 1 0.8
Struma Ovarii 1 0.8
Atypical hyperplasia* 1 0.8
Hyperplasia* 1 0.8
NED = no evidence of disease; * endometrium
Table 4 Number of patients with abnormal ovarian screening test results and number of repeat tests among different
risk groups
Risk group (Total no. pts) No of pts with abnormal test result No of repeat tests Prophylactic BSO because of abnormal test
CA125 (%) TVUS (%) CA125 (%) TVUS (%) CA125 TVUS
High risk (397) 37* (9) 65* (16) 54 (14) 98 (25) - 7
Moderate risk (112) 5 (4) 4 (4) 3** (3) 4 (6) 1 -
Low risk (36) 1 (3) 2 (6) 2 (6) 6 (17) - -
TVUS = transvaginal ultrasound; * includes 1 patient diagnosed with advanced ovarian cancer; ** no repeat tests in 2 patients: 1 patient with recurrent
progressive breast cancer and 1 pregnant patient
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Prophylactic BSO was performed in 25% of women
and in one case early stage ovarian cancer was found,
but on histology only. She had normal pre-operative
screening results. Transvaginal ultrasound and CA125
measurements as screening tests are known to have
their limitations. High false-positive rates have been
identified, especially in pre-menopausal women, result-
ing in a high number of re-call visits, anxiety through
equivocal test results, and even, unnecessary surgical
intervention [14-16]. In our study we found at least one
elevated CA125 in 43 women (8%) and at least one
abnormal transvaginal ultrasound in 71 women (13%).
In the majority of cases the repeat tests showed normal
results, although in 8 women a BSO was performed due
to a persistently abnormal test result. No ovarian cancer
was found in these women. Other studies have shown a
significant number of abnormal CA125 results and
transvaginal ultrasounds during surveillance [15]. Oei et
al. screened 512 high-risk women and found abnormal-
ities in 21% of all transvaginal ultrasounds and in 4% of
all CA125 measurements [17]. The majority of these
abnormal results disappeared within 3-6 months, result-
ing in a high number of unnecessary re-calls. Meeuwis-
sen et al. observed abnormal results in 19% of 383 high-
risk women, with 64% of them returning to normal
spontaneously [18].
The limitation of our study is that it has not been
conducted in the form of a robust prospective protocol,
but was an analysis of the clinical management guide-
lines at the time. Screening results were interpreted and
acted on by clinicians involved with no defined protocol
other than using the RMI only. Our study revealed a
significant number of re-calls for repeat screening tests.
No early stage ovarian cancer was identified at annual
screening by serum CA125 and/or transvaginal ultra-
sound. Of the two ovarian cases found, one early stage
ovarian cancer was found at prophylactic BSO. The
other case was found during screening and presented
with an advanced ovarian cancer. Both patients had
been under surveillance for more than 4 years and had
no abnormal results in their previous annual screening
rounds. Several studies have already reported that
annual screening of high-risk women will not reduce
mortality from ovarian cancer [6,19]. A large study of
3532 high-risk women screened annually with transvagi-
nal ultrasound and CA125 did not show any benefit in
survival; the majority of ovarian cancer cases was found
in an advanced stage [7]. Another study including 241
BRCA positive women who underwent ovarian surveil-
lance concluded low sensitivity and positive predictive
values of ovarian screening modalities and no additional
benefit from screening [8].
More sophisticated screening criteria have been
developed since the start of our study and we are
awaiting the results of a large UK multi-centre trial,
the UKFOCCS trial to clarify the role of different algo-
rithms of ovarian screening in women with an
increased genetic risk to assess if this improves upon
the annual re-call algorithm. Since no effective screen-
ing programme has yet been identified, prophylactic
BSO should be advised to all high-risk women after
they completed their family which will reduce the risk
of ovarian cancer associated with BRCA1 or BRCA2
mutation by 70-96% [20-22].
In conclusion, this study assessed the role of annual
ovarian screening in women with a family history of
ovarian cancer stratified into 3 different risk-groups. No
early stage ovarian cancer was picked up at annual
screening. This approach to screening led to a signifi-
cant number of re-calls for repeat screening tests.
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